文献速递眼底病与葡萄膜炎神经眼科

黑色素瘤、其他癌症及免疫检查点抑制剂治疗中眼科不良事件的群体频率

Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
PubMed 文献 · Am J Ophthalmol · 2021-02-15

该回顾性队列研究基于Kaiser Permanente南加州电子健康记录,分析2011至2018年间诊断为眼科免疫相关不良事件(OirAEs)的患者。研究发现癌症患者OirAEs患病率显著高于无癌症患者,且黑色素瘤患者接受ICI治疗后1年葡萄膜炎发生率显著高于非黑色素瘤癌症患者。

要点

  • 癌症患者中葡萄膜炎和特定神经眼科诊断的总体患病率高于无癌症患者。
  • 黑色素瘤患者接受任何ICI治疗后的1年葡萄膜炎发生率显著高于非黑色素瘤癌症患者。
  • 有葡萄膜炎病史的ICI治疗患者1年复发率高。

核心结论

  • 癌症患者中所有OirAEs的患病率显著高于无癌症患者。
  • 黑色素瘤患者接受ICI治疗后的葡萄膜炎风险较非黑色素瘤癌症患者特异性升高。

研究设计与样本

  • 主要暴露因素为既往启动ICI治疗和潜在癌症诊断。
  • 在黑色素瘤、非黑色素瘤癌症和无癌症患者中评估OirAEs的风险调整患病率。
  • 在接受ICI治疗的黑色素瘤和非黑色素瘤患者中确定OirAEs的1年发病率和既往眼科疾病复发情况。

主要发现

  • 在4,695,669名独特患者中,9.9%有癌症诊断,其中2.8%诊断为黑色素瘤。
  • 无论是否接受ICI治疗,黑色素瘤患者中葡萄膜炎和特定神经眼科诊断的总体患病率为341.8/100,000患者年,非黑色素瘤癌症患者为369.6/100,000患者年,无癌症患者为142.2/100,000患者年。
  • 共有2,911名独特患者接受了ICI治疗。
  • 与非黑色素瘤癌症患者相比,接受任何ICI治疗的黑色素瘤患者1年葡萄膜炎发生率升高(1.2% vs 0.2%;风险调整比值比6.45)。
  • 在ICI治疗且有既往葡萄膜炎病史的患者中观察到1年葡萄膜炎复发率高。

关键数值与推荐

  • 黑色素瘤患者葡萄膜炎和特定神经眼科诊断的总体患病率为341.8/100,000患者年。
  • 非黑色素瘤癌症患者葡萄膜炎和特定神经眼科诊断的总体患病率为369.6/100,000患者年。
  • 无癌症患者葡萄膜炎和特定神经眼科诊断的总体患病率为142.2/100,000患者年。
  • 接受任何ICI治疗的黑色素瘤患者1年葡萄膜炎发生率为1.2%,非黑色素瘤癌症患者为0.2%(风险调整比值比6.45)。

临床怎么用

  • 接受ICI治疗的患者可能需要基于潜在癌症诊断、特定ICI使用和葡萄膜炎病史进行不同的风险分层眼科监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the frequency of ophthalmic immune-related adverse events (OirAEs) in melanoma, other cancers, and after immune checkpoint inhibitor (ICI) treatment. DESIGN: Retrospective clinical cohort study. METHODS: This study identified patients diagnosed with OirAEs between January 1, 2011, and December 31, 2018, in the Kaiser Permanente Southern California electronic health records. The primary exposures of interest were prior initiation of ICIs and underlying cancer diagnosis. Risk-adjusted prevalence of OirAEs was evaluated in patients with melanoma, with nonmelanoma cancer, and without cancer. The 1-year incidence of OirAEs and recurrence of prior ophthalmic disease were identified in ICI-receiving patients with melanoma and nonmelanoma. RESULTS: Among 4,695,669 unique patients identified, 9.9% had a cancer diagnosis, of whom 2.8% had a diagnosis of melanoma. Overall prevalence for uveitis and selected neuro-ophthalmic diagnoses was 341.8/100,000 patient-years in patients with melanoma and 369.6/100,000 patient-years in patients with nonmelanoma cancer regardless of ICI treatment, compared with 142.2/100,000 patient-years in patients without cancer. A total of 2,911 unique patients received ICI therapy. Compared with patients with nonmelanoma cancer, patients with melanoma on any ICI had elevated 1-year incidence rates of uveitis (1.2% vs 0.2%; risk-adjusted odds ratio, 6.45). High 1-year recurrence rates for uveitis in ICI patients with a prior uveitis history were also observed. CONCLUSIONS: The prevalence of all OirAEs was substantially higher in patients with cancer, with ICI-related uveitis risk specifically increased in patients with melanoma compared with patients with nonmelanoma cancer. Evidence-based guidelines for ophthalmic monitoring of patients undergoing ICI treatment may require different risk stratifications based on underlying cancer diagnosis, specific ICI used, and prior history of uveitis.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Braun D, Getahun D, Chiu VY, et al. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment. Am J Ophthalmol. 2021. PMID: 33359682. doi:10.1016/j.ajo.2020.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。